Home HLA and Immune Genetics HLA-B*57:01 Test: Abacavir Hypersensitivity Risk and Results

HLA-B*57:01 Test: Abacavir Hypersensitivity Risk and Results

By
Vita Library
-
4
Learn how HLA-B*57:01 testing prevents abacavir hypersensitivity, what positive and negative results mean, when to test, symptoms to recognize, and how results guide HIV treatment.

The HLA-B*57:01 test identifies people at high risk of an immune-mediated hypersensitivity reaction to abacavir, an antiretroviral medicine used in some HIV treatment combinations. Testing should be completed before abacavir is prescribed, regardless of a person’s race or ancestry. A positive result means abacavir and any combination product containing it should not be used. A negative result makes immunologically confirmed abacavir hypersensitivity very unlikely, but it does not rule out every adverse reaction. Symptoms usually begin during the first six weeks and can involve fever, rash, fatigue, nausea, vomiting, abdominal symptoms, cough, sore throat, or shortness of breath. If hypersensitivity is suspected, abacavir must be stopped promptly and never restarted, because re-exposure can cause a rapid, severe, or fatal reaction. The result is inherited and remains valid for life, so a verified clinical result can usually be reused whenever HIV treatment is reviewed.

  • A positive HLA-B*57:01 result means abacavir is contraindicated, including abacavir-containing combination tablets.
  • A negative result greatly lowers the risk of true abacavir hypersensitivity, but does not exclude other medication reactions.
  • Testing is recommended before the first abacavir dose for every patient, not only for selected ancestry groups.
  • No fasting or medication changes are normally needed; testing uses blood, saliva, or a cheek-swab DNA sample.
  • Symptoms usually appear within the first six weeks and often affect two or more body systems.
  • Abacavir must never be restarted after suspected hypersensitivity, even when the HLA-B*57:01 result is negative.

Table of Contents

What the HLA-B*57:01 Test Measures

HLA-B57:01 is an inherited allele of the HLA-B gene. HLA-B produces a cell-surface protein that displays small peptide fragments to immune-system T cells. Abacavir can bind inside the peptide-binding groove of HLA-B57:01 and change which self-peptides are displayed. In susceptible people, this altered presentation can activate cytotoxic T cells and trigger a systemic hypersensitivity reaction.

The test asks one focused question: is HLA-B*57:01 present? It is not a viral-load test, HIV-resistance test, allergy skin test, or measure of how quickly abacavir is metabolized. It does not predict whether an abacavir-containing regimen will suppress HIV. It is a preventive pharmacogenetic test used before medication selection.

A person inherits one HLA-B allele from each biological parent. One copy of HLA-B57:01 is enough to classify the result as positive. The report may list both HLA-B alleles or simply state “detected” or “not detected.” The allele may be written as HLA-B57:01, HLA-B5701, or B57:01. The starred, colon-separated form is current HLA nomenclature.

HLA-B*57:01 frequency differs among populations. It is more common in people with some European ancestry than in many East Asian or African populations, but it occurs across diverse groups. Because ancestry is not a reliable way to exclude the allele—and because the consequence of missing it is serious—clinical HIV guidelines recommend testing all patients before abacavir initiation.

Prospective screening has transformed abacavir safety. Before routine testing, clinically suspected hypersensitivity occurred in roughly 5% to 8% of people beginning abacavir, although not all cases were immunologically confirmed. Screening plus avoidance in positive patients reduces confirmed HLA-B*57:01-mediated reactions to near zero when the result is correctly obtained and followed.

The genotype does not change over time. A documented negative result from a qualified laboratory generally does not need repeating. However, the team should confirm that the previous assay directly tested HLA-B*57:01 and that the result belongs to the correct patient.

Who Needs Testing and When

Anyone being considered for abacavir should have a documented negative HLA-B*57:01 result before the first dose. This includes adults, adolescents, children, and infants old enough to receive the medicine under the applicable treatment guidance. It also applies when abacavir is part of a fixed-dose combination rather than prescribed as a separate tablet or liquid.

Products and regimens can change over time, so clinicians and pharmacists should check the active ingredients rather than relying only on a brand name. Combination products containing abacavir remain unsuitable for an HLA-B*57:01-positive patient.

Testing is also needed when abacavir is being restarted and no reliable prior genotype is documented. A medication list that says “tolerated in the past” does not substitute for testing if the person is not currently taking abacavir. Previous tolerance lowers concern but does not provide the same standardized evidence as a verified negative genotype.

A person who is already taking abacavir continuously without symptoms presents a different situation. Most true hypersensitivity reactions occur early, generally within the first six weeks. Guidelines state that patients who are currently tolerating abacavir do not usually need testing solely to continue it. If testing is performed for another reason and unexpectedly returns positive, the HIV specialist should review the duration of uninterrupted therapy, the reliability of the result, and the risks of switching. The patient should not stop antiretroviral therapy without a replacement plan.

Testing should be ordered early enough that the result does not delay effective HIV treatment. Modern initial regimens often do not require abacavir, so antiretroviral therapy can usually begin with another recommended combination while information is gathered. In situations where abacavir is the preferred option, rapid genotyping may be useful.

HLA-B*57:01 testing is not used to decide whether a patient with symptoms is having abacavir hypersensitivity. If a reaction is suspected, clinical action takes priority. Waiting for a genotype before stopping the drug can be dangerous. Similarly, a negative result should not persuade a clinician to continue abacavir when the clinical picture strongly suggests hypersensitivity.

A previous suspected or confirmed abacavir hypersensitivity reaction is a permanent contraindication to rechallenge. Testing afterward does not make re-exposure safe. The event should be recorded clearly in allergy and medication-safety fields.

How Testing Is Performed

The test analyzes DNA from a blood sample, cheek swab, or saliva sample. Fasting is not required. Abacavir, other antiretrovirals, food, exercise, and ordinary illnesses do not change the inherited genotype.

Laboratories use several validated methods, including sequence-specific polymerase chain reaction, real-time PCR, probe-based genotyping, Sanger sequencing, and next-generation sequencing. A targeted assay reports whether HLA-B*57:01 is present. A broader HLA-B genetic test may identify both HLA-B alleles at higher resolution.

Turnaround can range from hours to several days. Sample quality problems may produce an indeterminate result. When that happens, the test should be repeated or performed by another validated method. An indeterminate result is not equivalent to negative and should not be used to authorize abacavir.

Clinical laboratories may use direct allele detection or a screening marker. Direct HLA-B57:01 typing is preferred across diverse populations. Some assays have used the HCP5 rs2395029 variant as a proxy because it is often inherited with HLA-B57:01 in people of European ancestry. That linkage is not equally reliable in every population, so a proxy-only result can be less dependable for universal clinical use.

The laboratory should be told about an allogeneic stem cell or bone marrow transplant. Blood after transplant may contain donor-derived DNA, which can report the donor’s HLA-B genotype rather than the recipient’s original genotype. A pre-transplant specimen or non-blood tissue may be needed. Solid-organ transplantation does not usually replace the recipient’s blood-forming cells, although unusual clinical circumstances should still be discussed with the laboratory.

Direct-to-consumer tests and research ancestry files may not type HLA-B*57:01 directly. HLA imputation from nearby markers can be inaccurate, especially in underrepresented populations. A consumer result should be confirmed in a qualified clinical laboratory before it affects an HIV regimen.

The report belongs in a durable part of the medical record. A scanned document, structured pharmacogenomics field, and medication decision-support alert are more useful than a temporary note. Patients can also keep a copy because they may receive HIV care in more than one health system.

Pre-test counseling can be brief but should distinguish genetic susceptibility from a current allergy. The patient does not need to have taken abacavir for the test to work. A positive result is not evidence that the immune system is weak, that HIV is more severe, or that relatives have HIV. It only indicates that this HLA molecule can present abacavir-altered peptides in a way linked to hypersensitivity. Clear counseling reduces stigma and makes the result easier to reuse.

Laboratories may report analytic sensitivity and specificity, but clinical performance also depends on correct patient identification and the prescriber following the result. A technically accurate test cannot prevent a reaction if abacavir is prescribed despite a positive result, if the result is filed under the wrong patient, or if a combination product is overlooked. Pharmacist verification and electronic alerts are therefore part of the safety system.

Understanding Positive, Negative, and Unclear Results

Positive result

A positive result means at least one HLA-B*57:01 allele was detected. Abacavir should not be prescribed. This recommendation applies even if the patient has never had a drug allergy and even if abacavir would otherwise be a convenient component of therapy.

Positive does not mean the person currently has an allergy, and it does not mean every exposure would certainly cause symptoms. Approximately half of carriers may not develop clinically apparent hypersensitivity, but there is no safe way to identify those individuals in advance. Because alternative antiretroviral options exist and rechallenge can be dangerous, avoidance is the standard response.

The result should be entered as a pharmacogenetic contraindication and linked to abacavir-containing products. Some records also place it in the allergy section to trigger prescribing alerts. The wording should specify “HLA-B*57:01 positive—avoid abacavir” rather than a vague entry such as “HIV medicine allergy.”

Negative result

A negative result means HLA-B*57:01 was not detected. The risk of immunologically confirmed abacavir hypersensitivity is extremely low, so abacavir can be considered if it is otherwise appropriate. A negative result does not guarantee that the medicine will be tolerated.

Negative patients can still experience:

  • nausea, diarrhea, headache, fatigue, or other non-allergic adverse effects
  • rash from abacavir or another medicine
  • liver or metabolic problems related to the full regimen
  • symptoms caused by infection, immune recovery, or another condition
  • a rare clinically suspected hypersensitivity syndrome not explained by HLA-B*57:01

Prescribers must still counsel patients about early symptoms. The boxed warning and clinical rule against rechallenge apply when hypersensitivity is suspected, regardless of genotype.

Indeterminate or discordant result

An indeterminate result means the assay could not establish whether the allele is present. Causes include inadequate DNA, contamination, rare allele interference, or insufficient resolution. Repeat testing should occur before abacavir is started.

Discordant results can occur when two laboratories used different methods, a sample was mislabeled, or testing after stem cell transplant captured donor DNA. The safest approach is to pause abacavir planning, review the original reports, and obtain high-resolution clinical testing. When one credible result is positive and another negative, clinicians generally act cautiously until the discrepancy is resolved.

A report that lists HLA-B57 without the “:01” may be too low-resolution for abacavir guidance. Other HLA-B57 alleles are not automatically equivalent to HLA-B*57:01. The exact allele should be confirmed.

Recognizing Abacavir Hypersensitivity

Abacavir hypersensitivity is a systemic reaction, not simply a rash. Symptoms usually begin within the first six weeks, with a median onset around the first one to two weeks in classic descriptions. They often worsen with continued dosing and improve after the drug is stopped. Rash may be absent, so waiting for skin findings can delay recognition.

The syndrome commonly includes symptoms from at least two of these groups:

  • Fever: often a prominent early sign
  • Skin: diffuse rash, usually maculopapular or urticarial
  • General: fatigue, malaise, aching, or headache
  • Gastrointestinal: nausea, vomiting, diarrhea, or abdominal pain
  • Respiratory: cough, shortness of breath, sore throat, or chest symptoms

Laboratory abnormalities may include elevated liver enzymes, creatine kinase changes, or other nonspecific findings, but no single blood test confirms the reaction. Symptoms can resemble influenza, COVID-19, pneumonia, gastroenteritis, or a reaction to another antiretroviral. The medication timeline and pattern across body systems are central to diagnosis.

When hypersensitivity is suspected, abacavir is stopped immediately under medical direction. All abacavir-containing products are avoided permanently. Symptoms often begin improving within 48 to 72 hours, although severe cases require hospital care.

Rechallenge is dangerous. After the immune system has been primed, another dose can cause symptoms within hours, with severe hypotension, respiratory compromise, multiorgan failure, or death. Patients should never test their tolerance by taking another tablet. Leftover medicine should not be kept for future use, and all treating clinicians and pharmacists should know about the reaction.

A negative HLA-B*57:01 result does not change this emergency rule. Clinical trials and guidelines distinguish immunologically confirmed reactions from clinically suspected reactions, but bedside safety requires stopping abacavir when the syndrome is plausible. Later specialist review can refine the diagnosis without exposing the patient again.

How the Result Affects HIV Treatment

HLA-B*57:01 is one part of antiretroviral selection. The HIV clinician also considers viral resistance, viral load, kidney and liver function, hepatitis B status, cardiovascular and metabolic factors, pregnancy, age, drug interactions, adherence needs, and access.

A negative result permits—but does not require—abacavir use. Abacavir is commonly paired with lamivudine and may be combined with dolutegravir in a fixed-dose regimen. The regimen must still fit current treatment guidelines and the patient’s resistance profile. Abacavir and lamivudine do not provide adequate treatment for hepatitis B coinfection, so a person with chronic hepatitis B usually needs agents active against both HIV and hepatitis B.

A positive result removes abacavir from consideration. Alternatives often use tenofovir alafenamide or tenofovir disoproxil fumarate with emtricitabine or lamivudine, combined with an integrase inhibitor or another recommended anchor drug. The choice depends on kidney function, bone health, hepatitis B status, pregnancy considerations, interactions, and treatment history.

The result does not tell clinicians whether abacavir increases cardiovascular risk for a particular person. Observational studies and pooled analyses have produced differing conclusions about myocardial infarction risk. Clinicians evaluate cardiovascular disease separately and may prefer another backbone in people with high baseline risk, even when HLA-B*57:01 is negative.

For children, formulation availability, weight-based dosing, swallowing ability, and resistance history matter. HLA-B*57:01 testing remains mandatory before abacavir. For infants, clinicians follow age-specific antiretroviral guidance because approval and dosing differ from older children.

For people with an undetectable viral load who are switching therapy, the genotype remains relevant even when abacavir is introduced only as part of a simplification strategy. A prior negative result can be reused. If no result is available, testing should occur before the switch rather than after the first dose.

Pharmacogenetic testing should not delay treatment of newly diagnosed HIV. The care team can select a potent non-abacavir regimen immediately and revisit options when all baseline results are available. Rapid initiation and genetic safety can both be achieved.

Limitations, Recordkeeping, and Family Implications

The HLA-B*57:01 test has excellent clinical utility, but it does not replace medication counseling. Its strongest performance applies to immunologically confirmed abacavir hypersensitivity. Clinical diagnosis is less specific because infections and reactions to other drugs can look similar.

Common interpretation errors include:

  • treating a negative result as permission to ignore symptoms
  • assuming a positive result predicts HIV treatment failure
  • confusing HLA-B*57:01 with any HLA-B57 allele
  • using an ancestry estimate or proxy SNP as definitive clinical typing
  • restarting abacavir after a suspected reaction because the genotype was negative
  • failing to recognize abacavir inside a combination tablet
  • storing the result only in a note that future prescribers may not see

The genotype is inherited, so first-degree relatives may have an increased chance of carrying it. Routine cascade testing is not usually needed because HLA-B*57:01 does not cause a disease by itself. A relative should be tested if abacavir is being considered for that person. The result should not be used for paternity, ancestry, or disease-risk conclusions outside its validated context.

HLA-B*57:01 is also associated with some other drug reactions, including flucloxacillin-related liver injury and pazopanib-associated liver enzyme elevations, but the clinical recommendations differ. A positive result does not automatically contraindicate every medicine with a reported association. Each drug–gene pair requires its own evidence and guideline interpretation.

If a result appears inconsistent with a past report, the laboratory can repeat direct typing. A genetic variant result framework used for rare disease is not directly applicable here: HLA-B*57:01 is not labeled pathogenic or benign. It is reported as a pharmacogenetic allele with a defined medication-risk implication.

Patients can ask for the exact laboratory report, keep it with their medication records, and verify that abacavir appears on the avoid list when positive. Strong recordkeeping prevents accidental exposure years later and allows a negative result to support future treatment choices without unnecessary repeat testing.

A result should remain visible in the medication record even if abacavir is not currently prescribed. Patients can carry a wallet card or add the allele and abacavir avoidance to emergency health information. Because the genotype is lifelong, a documented validated positive result should not be retested in hopes that it has changed.

A negative result removes the major known HLA-associated risk but does not make every symptom harmless. Fever, rash, gastrointestinal symptoms, breathing symptoms, or severe constitutional illness after starting abacavir still require immediate prescriber contact. Other medicines, infections, and immune reactions may resemble hypersensitivity.

The safest prescribing workflow links laboratory reporting to an electronic alert, pharmacist review, and patient education before the first dose. Testing after symptoms begin is not a substitute for stopping suspected abacavir and obtaining urgent assessment. Rechallenge after a clinically suspected reaction is dangerous even when a later genotype is negative, because the original episode may have been true hypersensitivity through an atypical mechanism or the test history may be uncertain.

References

Disclaimer

This information is educational and does not replace HIV-specialist care or individualized prescribing. Do not start, stop, or restart abacavir without a clinician-directed antiretroviral plan. Suspected abacavir hypersensitivity requires immediate medical assessment, permanent discontinuation, and no rechallenge.

RELATED ARTICLESMORE FROM AUTHOR